Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
February 25, 2021 7:00 AM ESTWorldwide Ocaliva® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year
Intercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 million and Non-GAAP Adjusted Operating Expense Guidance of $380 to $410 million
FDA interactions remain ongoing regarding newly identified safety signal (NISS) for liver disorder in a subset of PBC patients with cirrhosis; Update to Ocaliva label expected Â
Anticipated readout of REVERSE Phase 3 study in compensated... More
